EZH2, EED, and SUZ12 are commonly upregulated and are also susceptible to mutations in certain cancers such as breast, colorectal, and prostate cancer.302,305 Thus, targeting PRC2 for cancer treatment has become an effective strategy. Here, EZH2 is linked to cancer.